Trial Profile
Randomised phase II study of hepatic arterial infusion with floxuridine and dexamethasone with IV [intravenous] systemic chemotherapy with and without bevacisumab (mab to vascular endothelial growth factor-A) in patients with resected hepatic metastases from colorectal cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Dexamethasone; Floxuridine; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- 26 Apr 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 26 Apr 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 26 Apr 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.